Advertisement

Topics

Clinical Trials About "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" RSS

06:22 EDT 23rd March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" on BioPortfolio

We have published hundreds of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 news stories on BioPortfolio along with dozens of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Clinical Trials and PubMed Articles about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Companies in our database. You can also find out about relevant Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Drugs and Medications on this site too.

Showing "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" Clinical Trials 1–25 of 585

Extremely Relevant

The Validation of a Novel Adherence Method for Oral Oncolytics

The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics and to validate a currently available smart phone application (iRxReminder) partnered with an automated dispensing device, a "Pod", in affecting patient adherence. The rationale for this study is that medication adherence to oncolytics varies and strategies are needed to improve it.


A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with gemcitabine is effective and safe in the treatment of patients with advanced pancreatic cancer.

Relevant

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.


Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus in combination with Paclitaxel and Carboplatin is effective and safe in the treatment of squamous cell carcinoma of the head and neck.

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

The purpose of this Phase 2 study is to investigate whether intravenous administration of a wild type reovirus (REOLYSIN®) in combination with paclitaxel and carboplatin is effective and safe in the treatment of Non-Small Cell Lung Cancer with KRAS or EGFR activation.

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing. This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide or pomalidomide. The study will also investigate the safety, side effects and effectiveness of this treatment combination. Pomalidomide and lenalidomide will be evaluated separately as two separate groups.

Impact of a Limitation Section on the Meta-analysis Results' Interpretation

Objective: The investigators aim to evaluate the impact of a " limitations " section in systematic review's abstract on results' interpretation by readers. Design: Randomized ratio 1:1 controlled trial with two parallel arms. Participants will be invited to participate in an online survey. Participants: Eligible participants are corresponding authors of randomized controlled trial published between 2010 and 2012 and referenced in pubmed Intervention: The investigators ...

REO13 Melanoma With of Without GM-CSF

Open-label, non-randomised, single centre study which will assess the presence of reovirus (Reolysin®), following intravenous administration with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF) given to patients prior to surgery for metastatic melanoma. All patients will receive an initial low 'immunisation' dose of intravenous reovirus. Patients will be enrolled sequentially in to each of the two cohorts receiving either reovirus alone, or reovirus plus G...

Hypertension in Minorities Database-Workshop and Publication

To develop a comprehensive database publication (databook) utilizing available published and unpublished data on the prevalence of hypertension and its treatment and control in selected minority populations in the United States -- Hispanic, Asian and American Indian.

Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes

RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available

Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck

RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available

A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects

The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years, according to the Essen methods (1-1-1-1-1) vaccination.

Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates

Bisphosphonates (BP) are widely used in the prevention and treatment of osteoporosis in postmenopausal women and older men. Recently, there has been concern about the risk of adverse events after several years of using these agents. This has resulted in a publication from the Food and Drug Administration that suggested that, for many individuals, a holiday from bisphosphonates might be considered after 4-5 years of continuous use. In that publication there was little, if any, g...

Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia

Dysfunctional chronic diffuse pain syndrome, concerning 2% of the French population, Fibromyalgia (FM) is classified either as a psychological disease or as a somatic disease. This dichotomous reasoning does not lead to a better understanding and does not allow the use or development of new psychological tools of care. The issue of the proximity between FM and depression highlighted by some authors and the presence of anxious comorbidities may arise at a different level, that ...

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Pevion Biotech has designed a therapeutic vaccine to treat patients who suffer from chronic hepatitis C virus infection. The vaccine is based on a combination of the PeviPRO and PeviTER platforms using synthetic peptide antigens from the hepatitis C virus. Generally, a cellular immune response by cytotoxic T-lymphocytes (CTL) seems to be crucial in overcoming a hepatitis C virus infection. In-depth research in recent years has shown that the cellular immune response is even mor...

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

The primary objectives of this study are: - To describe the immunogenicity of the 2018-2019 formulation of Fluzone Quadrivalent vaccine in children 6 to < 36 months of age and 3 to < 9 years of age, and in adults 18 to < 65 years of age, the immunogenicity of the 2018-2019 formulation of Flublok Quadrivalent vaccine in adults 18 to < 65 years of age, and the immunogenicity of the 2018-2019 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years o...

a Multifaceted Program for Improving Quality of Care in ICU

Medical errors that affect patient safety have generated huge concern since the publication of "To Err Is Human" 6 years ago [1]. Given the complexity of management in the intensive care unit (ICU) and the nature of human activities, critically ill patients are exposed to adverse events (AEs) induced by medical errors. A large number of studies have focused on AEs and medical errors in ICUs [2-6], one of their main goals being to identify strategies for preventing AEs and there...

Technical Performance of a New Cardiac Technology "IQ-SPECT" Applied to SCINTI-CT Myocardial Imaging With 99mTc-Sestamibi in Coronary Patients

Cardiological examination is one of the major directions in nuclear medicine for detection of myocardial ischemia in patients with suspected coronary artery disease. In Caen, they constitute 20% of the activity of nuclear medicine. It is evaluating a new versatile innovative technology (IQ-SPECT) for performing rapid nuclear cardiological examinations (4 minutes) and quality on a SCINTI-CT camera for correcting the mitigation. This technical solution IQ-SPECT was made available...

Subclavian Artery Plug Embolization (SAPE)

This is an observational, non-profit, ambispective study: a retrospective arm which will include about 80 cases treated in the period: August 2009 - March 2018, and a prospective arm in which intends to include patients treated starting from March 2018 until December 2018. (about 70 cases) The endovascular occlusion of the prevertebral subclavian artery was first used in Vascular surgery Departement at San Raffaele Hospital, in August 2009. In the first period (2009-2014) this ...

D2560C00015 FluMist Annual Safety Study 2018

This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.

Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy

ABSTRACT Background: Today, a wide range of pediatric cancers is treated by chemotherapy. More than 21 side effects of chemotherapy have been identified. Among those nausea; vomiting, infection and anemia are most common. The adverse effects are normally managed by the parents at home. Ineffective coping and lack of knowledge about chemotherapy side effect management leads parents stress. Contemporary research evidence that Nurse-led education, booklet providence ...

Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

Recruitment of participants to the study takes place at the urological department at Zealand University Hospital, Roskilde, Feb. 2018-April 2018. 10 people with diagnosis of renal cancer should be recruited in phases 1. Subsequently, biological materials from 100 patients with kidney cancer will be used from the national Biobank. In phase 3, 10 patients will be recruited for the final gene test.

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season.

This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.

Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil

The participants: 1800 full-term primiparas will be selected with ASA I-Ⅱgrade, 20 to 35 years old and weighing 55 to 90 kg in the investigator's hospital from may 2018 to December 2018. 1200 primiparas were divided into A and B according to the computer randomized numbers, and 600 parturients without labor analgesia in the same period were selected as group C, with 600 patients in each group. All parturients signed the informed consent form and were approved by the hospital ...


More From BioPortfolio on "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018"

Advertisement
Quick Search
Advertisement
Advertisement